BACKGROUND: The residual uraemic syndrome that is inadequately cleared by diffusion is thought to contribute to the poor outcome of maintenance dialysis patients. Haemodiafiltration combines diffusion and convection in a single therapy, conferring theoretical benefits over haemodialysis. However, only few randomised comparisons have been carried out. METHODS: The prospective crossover clinical evaluation of high-flux ultrapure haemodialysis and online haemodiafiltration included 76 clinically stable patients on low-flux conventional bicarbonate buffered haemodialysis. They were randomized to high-flux haemodialysis or online haemodiafiltration (24 months) and switched to the alternative treatment (24 months). RESULTS:Removal of urea (Kt/V) and phosphate was significantly greater for online haemodiafiltration than for haemodialysis. Both high-flux haemodialysis and haemodiafiltration were associated with sustained reductions of pretreatment beta 2 microglobulin levels, however, the decrease was greater with haemodiafiltration. Both modes of renal replacement therapy significantly improved nutritional status and the haematopoietic response to rHu EPO. Under unmatched conditions (sodium and energy balance) haemodiafiltration was associated with a lower number of hypotensive episodes and partial improvement of quality of life. The incidence of death was low in both groups and did not differ among the two modes of renal replacement therapy. CONCLUSION: Online haemodiafiltration is a safe, effective and well tolerated therapy for end-stage renal disease patients even in the long run. Whether the dismal mortality rates of unselected end-stage renal disease patients can be changed by online haemodiafiltration remains to be shown in large scale long-term trials.
RCT Entities:
BACKGROUND: The residual uraemic syndrome that is inadequately cleared by diffusion is thought to contribute to the poor outcome of maintenance dialysis patients. Haemodiafiltration combines diffusion and convection in a single therapy, conferring theoretical benefits over haemodialysis. However, only few randomised comparisons have been carried out. METHODS: The prospective crossover clinical evaluation of high-flux ultrapure haemodialysis and online haemodiafiltration included 76 clinically stable patients on low-flux conventional bicarbonate buffered haemodialysis. They were randomized to high-flux haemodialysis or online haemodiafiltration (24 months) and switched to the alternative treatment (24 months). RESULTS: Removal of urea (Kt/V) and phosphate was significantly greater for online haemodiafiltration than for haemodialysis. Both high-flux haemodialysis and haemodiafiltration were associated with sustained reductions of pretreatment beta 2 microglobulin levels, however, the decrease was greater with haemodiafiltration. Both modes of renal replacement therapy significantly improved nutritional status and the haematopoietic response to rHu EPO. Under unmatched conditions (sodium and energy balance) haemodiafiltration was associated with a lower number of hypotensive episodes and partial improvement of quality of life. The incidence of death was low in both groups and did not differ among the two modes of renal replacement therapy. CONCLUSION: Online haemodiafiltration is a safe, effective and well tolerated therapy for end-stage renal diseasepatients even in the long run. Whether the dismal mortality rates of unselected end-stage renal diseasepatients can be changed by online haemodiafiltration remains to be shown in large scale long-term trials.
Authors: Muriel P C Grooteman; Marinus A van den Dorpel; Michiel L Bots; E Lars Penne; Neelke C van der Weerd; Albert H A Mazairac; Claire H den Hoedt; Ingeborg van der Tweel; Renée Lévesque; Menso J Nubé; Piet M ter Wee; Peter J Blankestijn Journal: J Am Soc Nephrol Date: 2012-04-26 Impact factor: 10.121
Authors: Alexandra Moura; José Madureira; Pablo Alija; João Carlos Fernandes; José Gerardo Oliveira; Martin Lopez; Madalena Filgueiras; Leonilde Amado; Maria Sameiro-Faria; Vasco Miranda; Alice Santos-Silva; Elísio Costa Journal: Aging Dis Date: 2014-05-25 Impact factor: 6.745
Authors: E Lars Penne; Neelke C van der Weerd; Peter J Blankestijn; Marinus A van den Dorpel; Muriel P C Grooteman; Menso J Nubé; Piet M Ter Wee; Renée Lévesque; Michiel L Bots Journal: Clin J Am Soc Nephrol Date: 2009-11-12 Impact factor: 8.237
Authors: Enric Vilar; Andrew C Fry; David Wellsted; James E Tattersall; Roger N Greenwood; Ken Farrington Journal: Clin J Am Soc Nephrol Date: 2009-10-09 Impact factor: 8.237
Authors: Albert H A Mazairac; G Ardine de Wit; Muriel P C Grooteman; E Lars Penne; Neelke C van der Weerd; Claire H den Hoedt; Renée Lévesque; Marinus A van den Dorpel; Menso J Nubé; Piet M ter Wee; Michiel L Bots; Peter J Blankestijn Journal: Clin J Am Soc Nephrol Date: 2012-11-02 Impact factor: 8.237
Authors: Ria Arnold; Bruce A Pussell; Timothy J Pianta; Virginija Grinius; Cindy S-Y Lin; Matthew C Kiernan; James Howells; Meg J Jardine; Arun V Krishnan Journal: PLoS One Date: 2013-03-11 Impact factor: 3.240